COVID-19_1170x250

COVID-19 Vaccines Resources

By AHRMM

When the novel coronavirus (SARS-CoV-2) emerged in late 2019, hundreds of individuals and organizations around the world quickly mobilized to develop a vaccine for COVID-19, the disease caused by the virus.

This webpage is intended to help keep the supply chain field informed of important updates related to the progress and distribution of COVID-19 vaccines. Resources and information will be added and updated often as new developments occur.

<< Return to AHRMM's COVID-19 page.

AHA COVID-19 Vaccines and Therapeutics

When the novel coronavirus (SARS-CoV-2) emerged in late 2019, hundreds of individuals and organizations around the world quickly mobilized to develop a vaccine for COVID-19, the disease caused by the virus. As the virus surged in 2020, therapeutics were developed to treat those with COVID-19 in outpatient and inpatient settings. This webpage is intended to help keep the field informed of important updates related to the progress and distribution of COVID-19 vaccines, along with in-development therapeutics for patients with COVID-19.

CDC COVID-19 Vaccination Program Interim Playbook

This playbook serves as an interim playbook for state, territorial, tribal and local public health programs and their partners on how to plan and operationalize a vaccination response to COVID-19 within their jurisdictions.

 

Pfizer and BioNTech COVID-19 Vaccine Approval

On August 23, 2021, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.

Moderna COVID-19 Vaccine

Moderna COVID‑19 Vaccine is for use for active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. The vaccine contains a nucleoside-modified messenger RNA encoding the viral spike (S) glycoprotein of SARS-CoV-2 formulated in lipid particles. It is an investigational vaccine not licensed for any indication.

Johnson & Johnson-Janssen COVID-19 Vaccine

The Johnson & Johnson-Janssen COVID‑19 Vaccine is for active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. The vaccine contains a recombinant, replication-incompetent human adenovirus serotype 26 (Ad26) vector, encoding the SARS-CoV-2 viral spike (S) glycoprotein, stabilized in its pre-fusion form. It is an investigational vaccine not licensed for any indication.

AHRMM Webinar: COVID 19 Vaccine Supply, Distribution and Handling Overview: An Operation Warp Speed Panel Discussion

 

 

Webinar Recording and Handouts

Review the recording and materials that were made available at the December 16 webinar:

Access Webinar Recording

Access Presentation Handouts

Access Presentation Slides

Operation Warp Speed Videos

Review the videos provided by HHS and Operation Warp Speed:

View Five Things to Know About the COVID-19 Vaccine Timeline (Video)

Access Five Things to Know About Operation Warp Speed (Video)

Related Resources

White Papers
Consider how direct sourcing can enable access to PPE and the leading practices of building supply chain diversity and resiliency for the future in…
Guides/Reports
Though the health care industry is continuing to tackle the COVID-19 pandemic, many industry leaders are also looking to build a more resilient sup
Guides/Reports
As health care emerges from the COVID-19 pandemic, supply chain resiliency is a priority.
Webcast
COVID-19 has exposed the fragile nature of the health care supply chain, but it’s not the first public health crisis to do so. Michael Schiller,…
AHRMM What's New
Begin the year with a fresh organizational outlook using AHRMM’s Policies and Procedures Manual for the Health Care Supply Chain, 2nd Edition.…
Resources
AHRMM's recommendations help to avoid the inefficiencies, unnecessary product demand, cost and operational management associated with hospitals…